H-Index
17
Scimago Lab
powered by Scopus
eISSN: 1941-5923
call: +1.631.629.4328
Mon-Fri 10 am - 2 pm EST

Logo

Medical Science Monitor Basic Research
MSMbanner

Annals
ISI-Home

Get your full text copy in PDF

Long term survival in a patient with malign pleuralmesothelioma after gemcitabine treatment

Ugur Coskun, Nazan Gunel, Yesim Yildirim

CaseRepClinPractRev 2003; 4(2):92-93

ID: 429040


Background: Malign pleural mesothelioma is a chemoresistant tumor. Despite of advancement in chemoterapeutic agent, its prognosis remains poor.Case Report: Gemcitabine can be used as first line therapy in malign mesothelioma with a responce rate of 7% to 30%. Second line agents in this tumor are ineffective. We present a malign pleural mesothelioma (MPM) case treated with gemcitabine as a second line agent. Conclusions: Long term survival is achived with gemcitabine threapy in MPM.

This paper has been published under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
I agree